| scholarly article | Q13442814 |
| P356 | DOI | 10.3816/CBC.2003.N.039 |
| P698 | PubMed publication ID | 14715109 |
| P50 | author | Kjell Grankvist | Q40580136 |
| P2093 | author name string | Roger Henriksson | |
| Martin Erlanson | |||
| Jonas Bergh | |||
| Barbro K Linderholm | |||
| Lars Beckman | |||
| Birgitta Lindh | |||
| Bjorn Travelin | |||
| Kent Edin | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 340-347 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Clinical Breast Cancer | Q332245 |
| P1476 | title | Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers | |
| P478 | volume | 4 |
| Q46017879 | An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. |
| Q37882684 | Bevacizumab-induced hypertension: pathogenesis and management |
| Q33714638 | Clinical biomarkers for hypoxia targeting |
| Q42257587 | Contrast-Enhanced Ultrasonography Features of Breast Malignancies with Different Sizes: Correlation with Prognostic Factors |
| Q39313430 | D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects |
| Q35064517 | Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor |
| Q41871117 | Growth factor mediated signaling in pancreatic pathogenesis |
| Q44957730 | High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients |
| Q34605633 | Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues |
| Q36586901 | Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions |
| Q37321820 | Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. |
| Q44086998 | Peripheral enhancement of breast cancers on contrast-enhanced ultrasound: correlation with microvessel density and vascular endothelial growth factor expression |
| Q37234829 | Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) |
| Q36496394 | Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance |
| Q37264306 | Recent developments in breast-conserving surgery for breast cancer patients |
| Q35829182 | The -553 T/A polymorphism in the promoter region of the FGF2 gene is associated with increased breast cancer risk in Polish women |
| Q37777872 | The Tumor Microenvironment in Non–Small-Cell Lung Cancer |
| Q46207244 | The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling |
| Q79409751 | The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma |
| Q37512303 | The role of fibroblast growth factors in tumor growth |
| Q37337541 | The value of expression of M2-PK and VEGF in patients with advanced gastric cancer |
| Q47966264 | bFGF in tumor tissue independently prognosticates disease outcome of a natural course of invasive breast cancer. |
Search more.